News

“We made great progress during 2008 in a number of areas,” said chief executive officer Henri A. Termeer. “We delivered strong financial results, continued to grow our existing

Edward Richmond, formerly the executive vice president of operations, will assume the new position of executive vice president of customer solutions focusing on global customer service, program management,

The company has granted the underwriter of the offering a 45-day option to purchase up to an additional 457,500 units to cover over-allotments, if any. Net proceeds of

Niravam (alprazolam orally disintegrating tablets), Parcopa (carbidopa-levodopa orally disintegrating tablets) and Kemstro (baclofen orally disintegrating tablets) are central nervous system (CNS) products. Niravam and Parcopa have been commercially

The consortium, consisting of a total of 16 companies and research institutions from 11 countries. The project has been set up to standardize the pre-analytical handling of patient

“We’re extremely proud and fortunate to have Rusty join our team,” said Page Erickson, chairman of the board of directors. “As Celerus continues to grow and achieve profitability,

Acclarent intends to use the proceeds to continue commercialization of its Balloon Sinuplasty technology, as well as on-going investment in product development and clinical studies. Johnson & Johnson

The company has also announced that Al Kraus has been elected to chairman of the board. William Miller has stepped down as chairman after two years of service.

The collaboration is focused on identifying biomarkers in the field of systemic lupus erythematosus for clinical diagnostic purposes associated with the clinical development of Orencia, a Bristol-Myers Squibb